SMYD4 Promotes MYH9 Ubiquitination Through Lysine Monomethylation Modification to Inhibit Breast Cancer Progression

Overview

Journal Breast Cancer Res

Date 2025 Feb 10

PMID 39930544

Authors

Jin-Shuo Yang

Jun-Ming Cao

Rui Sun

Xue-Jie Zhou

Zhao-Hui Chen

Bo-Wen Liu

Xiao-Feng Liu

Yue Yu

Xin Wang

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the leading cause of female mortality worldwide. (SET And MYND Domain Containing 4) SMYD4 has been reported to be a tumour suppressor. However, the molecular mechanism of SMYD4 remains unclear.

Methods: The expression level of SMYD4 in breast cancer cells was detected by qRT-PCR and western blot. The effect of SMYD4 was verified in vitro and in vivo. The interaction between SMYD4 and MYH9 was investigated by co‑IP assay. The regulation of SMYD4 on WNT signaling pathway was detected by luciferase reporter assay and ChIP analysis.

Results: This study found that SMYD4 downregulation was associated with poor prognosis. SMYD4 was performed as a tumor suppressor both in vitro and in vivo. SMYD4 was found to interact with the downstream protein MYH9 and impede WNT signaling pathway. Further studies revealed that SMYD4 impeded the binding of MYH9 to the CTNNB1 promoter region by promoting lysine monomethylation and ubiquitination degradation of MYH9.

Conclusions: These findings reveal the emerging character of SMYD4 in Wnt/β‑catenin signaling and bring new sights of gene interaction. The discovery of this SMYD4/MYH9/CTNNB1/WNT/β-Catenin signalling pathway axis suggests that SMYD4 is a potential therapeutic target for breast cancer.

References

Ponde N, Zardavas D, Piccart M . Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 2018; 16(1):27-44. DOI: 10.1038/s41571-018-0089-9. View

Malladi S, Macalinao D, Jin X, He L, Basnet H, Zou Y . Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 2016; 165(1):45-60. PMC: 4808520. DOI: 10.1016/j.cell.2016.02.025. View

Rueda-Robles A, Audano M, Alvarez-Mercado A, Rubio-Tomas T . Functions of SMYD proteins in biological processes: What do we know? An updated review. Arch Biochem Biophys. 2021; 712:109040. DOI: 10.1016/j.abb.2021.109040. View

Zhang Y, Alshammari E, Sobota J, Yang A, Li C, Yang Z . Unique SMYD5 Structure Revealed by AlphaFold Correlates with Its Functional Divergence. Biomolecules. 2022; 12(6). PMC: 9221539. DOI: 10.3390/biom12060783. View

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

Xu Z, Li P, Wei D, Wang Z, Bao Y, Sun J . NMMHC-IIA-dependent nuclear location of CXCR4 promotes migration and invasion in renal cell carcinoma. Oncol Rep. 2016; 36(5):2681-2688. DOI: 10.3892/or.2016.5082. View

Tian R, Tian J, Zuo X, Ren S, Zhang H, Liu H . RACK1 facilitates breast cancer progression by competitively inhibiting the binding of β-catenin to PSMD2 and enhancing the stability of β-catenin. Cell Death Dis. 2023; 14(10):685. PMC: 10582012. DOI: 10.1038/s41419-023-06191-3. View

Wang G, Shi C, He L, Li Y, Song W, Chen Z . Identification of the tumor metastasis-related tumor subgroups overexpressed NENF in triple-negative breast cancer by single-cell transcriptomics. Cancer Cell Int. 2024; 24(1):319. PMC: 11409682. DOI: 10.1186/s12935-024-03505-z. View

Wong G, Manore S, Doheny D, Lo H . STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges. Semin Cancer Biol. 2022; 86(Pt 3):84-106. PMC: 9714692. DOI: 10.1016/j.semcancer.2022.08.003. View

10.

Tracy C, Warren J, Szulik M, Wang L, Garcia J, Makaju A . The Smyd Family of Methyltransferases: Role in Cardiac and Skeletal Muscle Physiology and Pathology. Curr Opin Physiol. 2018; 1:140-152. PMC: 5807017. DOI: 10.1016/j.cophys.2017.10.001. View

11.

Leinhart K, Brown M . SET/MYND Lysine Methyltransferases Regulate Gene Transcription and Protein Activity. Genes (Basel). 2014; 2(1):210-8. PMC: 3924839. DOI: 10.3390/genes2010210. View

12.

Xu X, Zhang M, Xu F, Jiang S . Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020; 19(1):165. PMC: 7686704. DOI: 10.1186/s12943-020-01276-5. View

13.

Wei H, Li W, Zeng L, Ding N, Li K, Yu H . OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway. Mol Cancer. 2024; 23(1):124. PMC: 11157765. DOI: 10.1186/s12943-024-02016-9. View

14.

Thakur C, Qiu Y, Pawar A, Chen F . Epigenetic regulation of breast cancer metastasis. Cancer Metastasis Rev. 2023; 43(2):597-619. DOI: 10.1007/s10555-023-10146-7. View

15.

Ye G, Yang Q, Lei X, Zhu X, Li F, He J . Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis. Theranostics. 2020; 10(17):7545-7560. PMC: 7359096. DOI: 10.7150/thno.46001. View

16.

Zhang X, Huang Y, Shi X . Emerging roles of lysine methylation on non-histone proteins. Cell Mol Life Sci. 2015; 72(22):4257-72. PMC: 11114002. DOI: 10.1007/s00018-015-2001-4. View

17.

Rubio-Tomas T . The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system. Heliyon. 2021; 7(6):e07387. PMC: 8246384. DOI: 10.1016/j.heliyon.2021.e07387. View

18.

Greer E, Shi Y . Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012; 13(5):343-57. PMC: 4073795. DOI: 10.1038/nrg3173. View

19.

Han S, Zou H, Lee J, Han J, Kim H, Cheol J . miR-1307-3p Stimulates Breast Cancer Development and Progression by Targeting SMYD4. J Cancer. 2019; 10(2):441-448. PMC: 6360296. DOI: 10.7150/jca.30041. View

20.

Trayes K, Cokenakes S . Breast Cancer Treatment. Am Fam Physician. 2021; 104(2):171-178. View